



# Updates in the Field of Multiple Sclerosis

Friday, May 3, 2024, 8:00 AM — 4:00 PM EST  
Livestreamed via Zoom | In-Person at Yale West Campus, CT



Photo: Peter Vanderwerker

MS is the most common neurological disease to cause disability in young adults. More than one million people are living with MS in the US today. The field of multiple sclerosis is continually advancing as we improve our understanding of the disease and refine our approach to management.

There have been major updates over the past several years to the understanding of disease phenotype, approach to treatment, and improvements in imaging modalities. This symposium will update providers on these changes to enable improved clinical care and patient outcomes.

## RSVP & DETAILS:

[yale.cloud-cme.com/MS2024](https://yale.cloud-cme.com/MS2024)

## CONTACT:

Anne Stark | [cme@yale.edu](mailto:cme@yale.edu)

## PROGRAM OVERVIEW

**Check-in & Breakfast** (*in-person registrants*)  
8:00 AM—8:30 AM

**Lectures**  
8:30 AM—4:00 PM

**Lunch Break** (*provided for in-person registrants*)  
12:10 PM

**7.50 AMA PRA Category 1 Credits™**





## SYMPOSIUM DIRECTORS & SPEAKERS

### COURSE DIRECTORS

**Samantha Epstein MD**

*Assistant Professor of Neurology  
Division of Neuroimmunology  
Yale School of Medicine*

**Erin Longbrake MD, PhD, FAAN**

*Associate Professor of Neurology  
Program Director, Neuroimmunology  
Fellowship  
Director, Clinical Research in  
Neuroimmunology  
Yale School of Medicine*

**David A. Hafler MD, FANA**

*William S. and Lois Stiles Edgerly  
Professor of Neurology and  
Professor of Immunobiology  
Chair, Department of Neurology  
Yale School of Medicine  
Neurologist-in-Chief,  
Yale New Haven Hospital*

### SPEAKERS

**Michael Levy MD, PhD**

*Associate Professor, Harvard Medical School  
Research Director, Division of Neuroimmunology & Neuroinfectious Disease  
Director, Neuroimmunology Clinic and Research Laboratory  
Massachusetts General Hospital*

**Daniel Ontaneda MD, PhD**

*Staff Neurologist at Cleveland Clinic  
Professor of Neurology,  
Cleveland Clinic Lerner College of Medicine  
of Case Western Reserve University*

**David Pitt MD**

*Associate Professor of Neurology  
Yale School of Medicine*

**Daniel S. Reich MD, PhD**

*Professor Adjunct  
Yale School of Medicine  
Senior Investigator  
Translational Neuroradiology Section, NINDS*

**Sarah F. Wesley MD, MPH**

*Assistant Professor of Neurology at CUMC  
Department of Neurology | Division of Neuroimmunology  
Columbia University Vagelos College of Physicians & Surgeons  
Center for Translational & Computational Neuroimmunology*



**AGENDA** *subject to change*

- 8:00 AM Registration and Continental Breakfast
- 8:30 AM Welcome and Introduction  
*Samantha Epstein MD*
- 8:40 AM Overview of MS Pathophysiology / Genetics  
*David A. Hafler MD, FAAN*
- 9:10 AM Defining MS Phenotypes Using Key Pathologic Processes  
*David Pitt MD*
- 9:50 AM Recognizing Pre-Clinical MS as Part of the MS Spectrum  
*Erin Longbrake MD, PhD, FAAN*
- 10:30 AM Refreshments/ Break
- \*SPECIAL HIGHLIGHT: IMAGING IN MULTIPLE SCLEROSIS\***
- 10:50 AM Neuroimaging: Measures for Assessing MS Disease Progression  
*Daniel S. Reich MD, PhD*
- 11:30 AM Neuroimaging in MS and the Central Vein Sign  
*Daniel Ontaneda MD, PhD*
- 12:10 PM Lunch
- 1:00 PM Update in MS Disease Modifying Therapies  
*Sarah F. Wesley MD, MS*
- 1:40 PM Breakout Sessions – Case Studies in M.S.  
*Multiple Moderators*
- 2:30 PM Update in MS Clinical Trials  
*Samantha Epstein MD*
- 3:10 PM Myelin Oligodendrocyte Glycoprotein Antibody-Mediated Disease  
*Michael Levy MD, PhD*
- 3:50 PM Closing Remarks
- 4:00 PM Adjournment



## LEARNING OBJECTIVES

At the conclusion of this program, the participants should be able to:

- Describe the biologic basis of disease and role of the environment in the development of multiple sclerosis
- Review the appropriate use of neuroimaging techniques in diagnosis and monitoring disease progression for patients with multiple sclerosis
- Better navigate the use of immunomodulatory medications throughout different phases of the MS disease course
- Identify consensus diagnostic criteria and general approach to treatment for patients with myelin oligodendrocyte glycoprotein antibody-mediated disease (MOG-AD)

## REGISTRATION FEES

Registration fee\* includes breakfast, refreshment break, and lunch:

CATEGORY	ON OR BEFORE 2/29/2024	ON OR AFTER 3/01/2024
Physician	\$150	\$200
Nurse/PA/Allied Health Professional	\$75	\$100
Non-Yale Resident/Fellow/Student	\$25	\$50
Yale Resident/Fellow/Student	\$0, registration required	\$0, registration required
Yale Neuro Staff	\$0, registration required	\$0, registration required

*\*All cancellations must be received in writing (or via e-mail) at least one week prior to the start of the conference to receive a refund. Any requests for refunds received after this date, or by telephone, will not be honored.*

*†A letter of verification from department head must accompany registration. Letter should be sent separately to Yale CME at [cme@yale.edu](mailto:cme@yale.edu)*

### RSVP:

[yale.cloud-cme.com/MS2024](https://yale.cloud-cme.com/MS2024)



---

#### Accreditation Statement

The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

#### Designation Statement

Yale School of Medicine approves this live activity for a maximum of **7.5 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC POINTS ~ Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 7.5 Medical Knowledge Only MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) Part II program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

#### Disclosure Policy

It is the policy of Yale School of Medicine, Continuing Medical Education (CME), to ensure balance, independence, objectivity, and scientific rigor in all its educational programs. All individuals involved in the development and presentation of Accredited Continuing Education activities are required to disclose all financial relationship(s) with ineligible companies (those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients) that has occurred within the past 24 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. This information is disclosed to all activity participants prior to the commencement of the educational activity.

#### Mitigation of Financial Relationships Statement:

Yale Continuing Medical Education adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

#### Financial Statement

The Yale School of Medicine Department of Neurology, Section of Neuroimmunology/ Multiple Sclerosis is grateful to its supporters. They are acknowledged in all conference materials.